Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. - Wikidata - awgldk - TriplyDB

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.

http://www.wikidata.org/entity/Q33345474

about

State of the art management of metastatic gastroesophageal cancer Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors.Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial.Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.Oxaliplatin with biweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (modified FOLFOX 4) as a salvage therapy for patients with advanced gastric cancer.Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis.Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen).Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status.The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trials.Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.Tian Xian Liquid (TXL) induces apoptosis in HT-29 colon cancer cell in vitro and inhibits tumor growth in vivo.A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer Recent advances in chemotherapy for advanced gastric cancer Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer.Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline.Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer.Efficacy and safety of oxaliplatin, 5-Fluorouracil, and folinic Acid combination chemotherapy as first-line treatment in metastatic or recurrent gastric cancer Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer.A cost-benefit analysis of chemotherapy for gastric cancer.Palliative chemotherapy for advanced gastric cancer.Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer.Recent developments in chemotherapy of advanced gastric cancer.The emerging role of oxaliplatin in the treatment of gastric cancer.Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1 Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group.A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer.A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer

P2860

Q26779217-DD581C77-0F9E-4AAC-A2CE-1FAFD75184E4 Q28079705-B6245915-AD7C-4C38-81BE-6C45197FE4DD Q33242985-A2E83ADD-33E9-4F9A-BDED-25D25E20B92E Q33337970-D390115B-6E2C-49FE-87F4-2416A8D4A4C5 Q33360403-FF26E258-9A7C-44ED-8493-1BF1327EC9DA Q33361500-5E4D7B74-9C20-4E9D-B679-2EFC28CF0227 Q33366008-D0924543-E19A-4DB1-AFD8-F01EE18B17E0 Q33368773-B8CCBBFC-A67C-4D52-8D81-258255AC1607 Q33374059-ADA5A6D8-CB38-4113-BD9E-6F10801DCD60 Q33383287-FCC0FACE-FA6D-45E9-AA82-B172755ED77D Q33387297-D0BDD08E-73BF-446C-9274-C882CE440460 Q33389036-9E4481E7-7D10-405D-9464-1F80110D361F Q33393039-977A6F27-5D90-484B-88FA-1E65F225EF3D Q33399154-548D7252-9E03-4666-B40E-B6BE3CF863FA Q33399530-B882CE24-A697-4E73-9811-0A593069C873 Q33402018-F26549D2-5CB2-42FC-91A5-2DE6CBD826C5 Q33405235-597500B8-768A-48E8-9A5E-3ED4D9475D51 Q33432145-6F97160C-D54B-4E63-9757-83A56D1F6088 Q33728364-DB9ABE02-7D12-4E01-A155-6B275898D532 Q34053882-02A15453-5DD2-4838-B5F7-4649D51D8024 Q34344182-6EFF3E59-7D1F-4F8D-A42B-6832AFCC3D36 Q34389753-7A4B63A9-9ECB-4FF3-8253-E3C0F3B76DA0 Q34594956-F54F9886-DD42-4A02-84CD-6F69D763B1E0 Q34670947-49EA48EE-1C24-46FA-9B2F-F65C7924D8C8 Q35000576-936094B1-496D-4FB7-8349-60F34ADBEB54 Q35019148-01C9C933-74CE-4BD3-BAB2-FD705A4DD27A Q35076251-1E855452-AE5E-46FE-B07F-F54B437B5558 Q35340883-FBB0D141-7689-44B8-87C4-15A50AA55048 Q35812808-12CEB064-CF88-404C-ADDA-622F2E9BD4A4 Q35906916-62798847-166B-49DB-8FE2-36EC4118FE39 Q35936039-DCB47B92-63A3-4A1A-89C7-1948288A1EA9 Q35948108-0305743D-E935-4C18-98D5-4A6ABCB023FB Q36090047-C71649AF-9711-4920-BCB3-5407D55C7373 Q36376345-57F51376-8A8C-4EC1-B3DA-1FDFA9FB6AE6 Q36453663-1C432366-EF4D-4968-BDA2-9540C81CEE48 Q36459767-A1DF2BCC-931D-4FD3-B21C-500F5A41C071 Q36594055-F186BA18-EE7B-4B3D-85D7-BE453C4447CA Q36609591-CC1BEBC8-58A4-4494-8984-FC5B6C11CB6F Q36611088-C27780CF-9DCE-4F8E-AA3A-B77FAFF5FCC8 Q36612039-D52A6FB3-F9FD-46CB-A8E0-82F65BA52C2C

P2860

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.

http://www.wikidata.org/entity/Q33345474

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Phase II study of oxaliplatin, ...... tatic gastric cancer patients.

@ast

Phase II study of oxaliplatin, ...... tatic gastric cancer patients.

@en

type

label

Phase II study of oxaliplatin, ...... tatic gastric cancer patients.

@ast

Phase II study of oxaliplatin, ...... tatic gastric cancer patients.

@en

prefLabel

Phase II study of oxaliplatin, ...... tatic gastric cancer patients.

@ast

Phase II study of oxaliplatin, ...... tatic gastric cancer patients.

@en

P1433

Q33345474-7807F4A7-6E2A-48EF-92AC-BE8FF8B72FE5

P1476

Q33345474-378A2447-C14F-4E1B-AE2E-956C0D17D7A5

P2093

Q33345474-14A025E4-3CC1-4EEF-831C-D61EE76CC6BA

Q33345474-631D8C47-7823-4C7E-83BD-FA830EBE2B93

Q33345474-67A519B3-1AC0-4A1C-AD32-68C47FA10F39

Q33345474-78FF86F3-C209-4170-946A-FDE52D1FC3A6

Q33345474-7B39A4B1-A1CC-49A0-9E5D-260155DDFA99

Q33345474-86673BC0-5834-4974-A57C-11BBE1838264

Q33345474-9FF9F578-9AC7-4235-BD04-BD4F502CEF3D

Q33345474-B0560315-E9F2-4A6C-B40D-5D812960731A

Q33345474-B24B2AE1-028F-4725-9EB6-423100FC8BE6

Q33345474-CEDA2DE0-391A-4BF2-BBD4-B24997F36125

P304

Q33345474-19A094CC-CD32-424A-A975-4DA5612558FB

P31

Q33345474-7533D19D-AD8E-4E85-BC18-C45608DCB4AF

P356

Q33345474-1D15156E-54A1-4CB5-811B-96D5F616C8F1

P407

Q33345474-B8595ECF-409A-4DDB-A6A2-D166A9514EDB

P433

Q33345474-3FA0C8CB-95D3-4B02-A404-377A7A647411

P478

Q33345474-6FE52497-000A-44CB-9579-78E570AC1CB4

P50

Q33345474-DC677293-2EC0-47BA-94FB-06739B408ECD

P577

Q33345474-3D9BDA39-B653-4EAE-97EB-30156587F2FA

P698

Q33345474-8F896ED9-F67A-4942-B9F9-0D6BC61CA811

P356

JCO.2002.02.021

P1433

Journal of Clinical Oncology

P1476

Phase II study of oxaliplatin, ...... tatic gastric cancer patients.

@en

P2093

A Taamma

http://www.w3.org/2001/XMLSchema#string

A de Gramont

http://www.w3.org/2001/XMLSchema#string

C Louvet

http://www.w3.org/2001/XMLSchema#string

D Levoir

http://www.w3.org/2001/XMLSchema#string

E Cvitkovic

http://www.w3.org/2001/XMLSchema#string

E François

http://www.w3.org/2001/XMLSchema#string

E Gamelin

http://www.w3.org/2001/XMLSchema#string

J H Jacob

http://www.w3.org/2001/XMLSchema#string

J M Tigaud

http://www.w3.org/2001/XMLSchema#string

J Y Douillard

http://www.w3.org/2001/XMLSchema#string

P304

4543-4548

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2002.02.021

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12454110

http://www.w3.org/2001/XMLSchema#string